Carolina Pape-Köhler
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Carolina Pape-Köhler has a total of 21 co-authors. Here are the top co-authors by number of shared publications:
- Annika Hoyer
Biostatistics and Medical Biometry, Medical School OWL, Bielefeld University, 33615 Bielefeld, Germany
3 shared publications - Joachim Feldkamp
Academic Department of General Internal Medicine, Endocrinology, Diabetes and Infectiology, Medical School and University Medical Center East Westphalia-Lippe, Bielefeld University, 33604 Bielefeld, Germany
3 shared publications - Sjaak Pouwels
Department of Surgery, Bielefeld University, Medical School and University Medical Center OWL, Campus Hospital Lippe, Detmold, Germany
3 shared publications - Stylianos Kopanos
Academic Department of General Internal Medicine, Endocrinology, Diabetes and Infectiology, Bielefeld University, Medical School and University Medical Center East Westphalia-Lippe, Bielefeld, Germany
2 shared publications Aline Tiegelkamp
1 shared publication- Andreas Dietrich
Department of Visceral, Transplant, Thoracic and Vascular Surgery, Leipzig University Hospital, Leipzig, Germany
1 shared publication
Latest Publications
- Open Access
- 2 September 2026
- Published by Elsevier in Obesity Pillars
- Vol. 20
Investigating seizures in bariatric surgery patients: Pre- and postoperative perspectives: A systematic review
- 2 September 2026
- Published by Elsevier in Obesity Pillars
- Vol. 20
Open AccessInvestigating seizures in bariatric surgery patients: Pre- and postoperative perspectives: A systematic review
- 21 July 2026
- Published by Springer Nature
- p. 237-253
Schwangerschaft mit bariatrischen Voroperationen
- Open Access
- 2 July 2026
- Published by MDPI AG in Metabolites
- Vol. 16 (7) , 465
Thyroid Hormone Treatment and Breast Cancer Risk in Women: A Systematic Review and Meta-Analysis of Observational Studies
Objective: Thyroid hormone treatment is the standard therapy for hypothyroidism, particularly in women. Concerns have been raised that exogenous thyroid hormone use may increase breast cancer risk, but evidence remains inconclusive. This study aimed to systematically review and synthesize observational evidence on the association between thyroid hormone treatment and breast cancer risk in women. Design: We conducted a systematic review and meta-analysis of observational studies. Methods: MEDLINE, EMBASE, and Web of Science were searched from January 1976 to February 2025. Eligible studies assessed breast cancer incidence in adult women receiving thyroid hormone treatment versus non-users. Pooled ORs were calculated. Findings from cohort studies reporting hazard ratios were synthesized qualitatively. Heterogeneity, publication bias, and certainty of evidence were assessed. PROSPERO ID: CRD42022348966. Results: Four case–control studies including 221,254 women receiving thyroid hormone treatment and 4,385,666 controls were included in the prespecified primary OR-based meta-analysis. In the primary random-effects meta-analysis, thyroid hormone treatment showed a possible epidemiological signal with breast cancer risk (OR 1.43, 95% CI: 0.90–2.28; I2 = 94.3%), although the confidence interval crossed unity and heterogeneity was substantial. Formal assessment of publication bias was performed but should be interpreted cautiously given the small number of included studies. The certainty of evidence was rated as low due to heterogeneity, serious inconsistency and imprecision. Conclusions: Thyroid hormone treatment was associated with a possible epidemiological signal for breast cancer in observational studies; however, the primary pooled estimate was not statistically significant and should be interpreted as hypothesis-generating because of substantial heterogeneity and residual confounding. Further well-designed prospective studies are required before causal or clinical inferences can be made.
- 2 July 2026
- Published by MDPI AG in Metabolites
- Vol. 16 (7) , 465
Open AccessThyroid Hormone Treatment and Breast Cancer Risk in Women: A Systematic Review and Meta-Analysis of Observational Studies
Objective: Thyroid hormone treatment is the standard therapy for hypothyroidism, particularly in women. Concerns have been raised that exogenous thyroid hormone use may increase breast cancer risk, but evidence remains inconclusive. This study aimed to systematically review and synthesize observational evidence on the association between thyroid hormone treatment and breast cancer risk in women. Design: We conducted a systematic review and meta-analysis of observational studies. Methods: MEDLINE, EMBASE, and Web of Science were searched from January 1976 to February 2025. Eligible studies assessed breast cancer incidence in adult women receiving thyroid hormone treatment versus non-users. Pooled ORs were calculated. Findings from cohort studies reporting hazard ratios were synthesized qualitatively. Heterogeneity, publication bias, and certainty of evidence were assessed. PROSPERO ID: CRD42022348966. Results: Four case–control studies including 221,254 women receiving thyroid hormone treatment and 4,385,666 controls were included in the prespecified primary OR-based meta-analysis. In the primary random-effects meta-analysis, thyroid hormone treatment showed a possible epidemiological signal with breast cancer risk (OR 1.43, 95% CI: 0.90–2.28; I2 = 94.3%), although the confidence interval crossed unity and heterogeneity was substantial. Formal assessment of publication bias was performed but should be interpreted cautiously given the small number of included studies. The certainty of evidence was rated as low due to heterogeneity, serious inconsistency and imprecision. Conclusions: Thyroid hormone treatment was associated with a possible epidemiological signal for breast cancer in observational studies; however, the primary pooled estimate was not statistically significant and should be interpreted as hypothesis-generating because of substantial heterogeneity and residual confounding. Further well-designed prospective studies are required before causal or clinical inferences can be made.
- Open Access
- 16 April 2026
- Published by Springer Nature in Obesity Surgery
- Vol. 36 (5) , 2527-2533
New Year’s Resolution or Spring Feelings? Effect of Month and Season on First Presentation and Short-Term Outcome in Metabolic and Bariatric Surgery
Background: While seasonal fluctuations in health behaviors such as dieting are well known, little is known about their influence on metabolic bariatric surgery (MBS) consultation timing. This study examines whether the season of first clinical presentation for MBS differs by sex and whether timing impacts early outcomes. Materials and methods: Data from 21,396 patients in the German StuDoQ/MBE registry (2014–2019) were analyzed. Monthly and seasonal presentation probabilities were compared by sex. Logistic regression assessed predictors of early-year consultation. Linear mixed models with random intercepts were used to evaluate the effect on weight loss at 3 and 12 months postoperatively. Results: Presentation patterns differed significantly between sexes. Women presented more frequently in spring and summer, while men showed a clear peak in the first quarter, aligning with calendar-based triggers like New Year’s resolutions. These trends suggest sex-specific motivators: body image awareness in women versus functional limitations and external cues in men. Despite seasonal variation in consultation timing, postoperative weight loss outcomes showed no statistically significant differences across all seasons. Conclusion: The timing of MBS consultation might be influenced by seasonal and sex-specific behavioral patterns. However, outcomes are unaffected by the time of year patients enter treatment. Recognizing these trends can inform tailored patient communication and engagement strategies. Future bariatric programs may benefit from sex-sensitive, seasonally adaptive approaches to optimize patient readiness and long-term success.
- 16 April 2026
- Published by Springer Nature in Obesity Surgery
- Vol. 36 (5) , 2527-2533
Open AccessNew Year’s Resolution or Spring Feelings? Effect of Month and Season on First Presentation and Short-Term Outcome in Metabolic and Bariatric Surgery
Background: While seasonal fluctuations in health behaviors such as dieting are well known, little is known about their influence on metabolic bariatric surgery (MBS) consultation timing. This study examines whether the season of first clinical presentation for MBS differs by sex and whether timing impacts early outcomes. Materials and methods: Data from 21,396 patients in the German StuDoQ/MBE registry (2014–2019) were analyzed. Monthly and seasonal presentation probabilities were compared by sex. Logistic regression assessed predictors of early-year consultation. Linear mixed models with random intercepts were used to evaluate the effect on weight loss at 3 and 12 months postoperatively. Results: Presentation patterns differed significantly between sexes. Women presented more frequently in spring and summer, while men showed a clear peak in the first quarter, aligning with calendar-based triggers like New Year’s resolutions. These trends suggest sex-specific motivators: body image awareness in women versus functional limitations and external cues in men. Despite seasonal variation in consultation timing, postoperative weight loss outcomes showed no statistically significant differences across all seasons. Conclusion: The timing of MBS consultation might be influenced by seasonal and sex-specific behavioral patterns. However, outcomes are unaffected by the time of year patients enter treatment. Recognizing these trends can inform tailored patient communication and engagement strategies. Future bariatric programs may benefit from sex-sensitive, seasonally adaptive approaches to optimize patient readiness and long-term success.
- Open Access
- 31 March 2026
- Published by Elsevier in Surgery for Obesity and Related Diseases
- Vol. 22 (7) , 806-817
Metabolic and bariatric surgery in MAFLD: a meta-analysis of endocrine outcomes, fibrosis remission, and postoperative complications
- 31 March 2026
- Published by Elsevier in Surgery for Obesity and Related Diseases
- Vol. 22 (7) , 806-817
Open AccessMetabolic and bariatric surgery in MAFLD: a meta-analysis of endocrine outcomes, fibrosis remission, and postoperative complications
- Open Access
Continuous Glucose Monitoring Improves Weight Loss and Hypoglycemic Symptoms in a Non-Diabetic Bariatric Patient 14 Years After RYGB: A Case Report
Background and Clinical Significance: Roux-en-Y gastric bypass (RYGB) significantly alters glucose metabolism, yet managing glucose variability in patients undergoing bariatric surgery remains challenging. Continuous Glucose Monitoring (CGM) offers real-time insights into glucose fluctuations and may support long-term metabolic management in this population. This case highlights the utility of CGM in identifying postprandial glycemic variability and guiding dietary adjustments. Case Presentation: A 45-year-old female, 14 years post-RYGB, presented with symptoms including postprandial fatigue, nocturnal cravings, and unexplained weight gain, despite adherence to nutritional guidelines. Her BMI had decreased from 52 kg/m2 (pre-surgery) to 29 kg/m2. She was provided with a CGM device (FreeStyle Libre 3) by the clinical team and instructed to monitor glucose without modifying her routine initially. Data revealed significant glycemic variability, with peaks up to 220 mg/dL and hypoglycemic dips to 45 mg/dL. Based on this, she adjusted her diet by reducing non-complex carbohydrates and increasing vegetables, proteins, and complex carbohydrates. Within two weeks, her symptoms improved, including better sleep and energy levels, accompanied by a 3 kg weight loss following dietary adjustments informed by CGM feedback. Conclusions: This case suggests how CGM can empower patients having undergone bariatric surgery to manage glucose fluctuations through informed self-management. The patient’s ability to identify and address glucose variability without formal intervention highlights CGM’s potential as a supportive tool in long-term care. While further studies are needed, this case suggests CGM may benefit similar patients experiencing postprandial symptoms or weight regain after bariatric surgery.
Open AccessContinuous Glucose Monitoring Improves Weight Loss and Hypoglycemic Symptoms in a Non-Diabetic Bariatric Patient 14 Years After RYGB: A Case Report
Background and Clinical Significance: Roux-en-Y gastric bypass (RYGB) significantly alters glucose metabolism, yet managing glucose variability in patients undergoing bariatric surgery remains challenging. Continuous Glucose Monitoring (CGM) offers real-time insights into glucose fluctuations and may support long-term metabolic management in this population. This case highlights the utility of CGM in identifying postprandial glycemic variability and guiding dietary adjustments. Case Presentation: A 45-year-old female, 14 years post-RYGB, presented with symptoms including postprandial fatigue, nocturnal cravings, and unexplained weight gain, despite adherence to nutritional guidelines. Her BMI had decreased from 52 kg/m2 (pre-surgery) to 29 kg/m2. She was provided with a CGM device (FreeStyle Libre 3) by the clinical team and instructed to monitor glucose without modifying her routine initially. Data revealed significant glycemic variability, with peaks up to 220 mg/dL and hypoglycemic dips to 45 mg/dL. Based on this, she adjusted her diet by reducing non-complex carbohydrates and increasing vegetables, proteins, and complex carbohydrates. Within two weeks, her symptoms improved, including better sleep and energy levels, accompanied by a 3 kg weight loss following dietary adjustments informed by CGM feedback. Conclusions: This case suggests how CGM can empower patients having undergone bariatric surgery to manage glucose fluctuations through informed self-management. The patient’s ability to identify and address glucose variability without formal intervention highlights CGM’s potential as a supportive tool in long-term care. While further studies are needed, this case suggests CGM may benefit similar patients experiencing postprandial symptoms or weight regain after bariatric surgery.